Turn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases

Reuters

Jan 08

Turn <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases

Turn Therapeutics Inc. has released a corporate presentation detailing its pipeline and development strategy for inflammatory disease treatments. The company is advancing GX-03, a non-systemic, topical immunomodulator targeting IL-36 and related cytokines, with a primary focus on moderate to severe eczema. The Phase 2 trial for GX-03 is underway, with an interim analysis expected in the first quarter of 2026 and topline data anticipated in the second quarter of 2026. Phase 3 studies are expected to begin in the second half of 2026. Additional pipeline candidates include treatments for onychomycosis and psoriasis, as well as thermostable vaccine platforms. The company’s PermaFusion® technology underpins its proprietary drug delivery approach. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601380069"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601380069\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601380069?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 01:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601380069","market":"fut","top_or_hot":-1,"title":"Turn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Turn <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Turn Therapeutics Inc. has released a corporate presentation detailing its pipeline and development strategy for inflammatory disease treatments. The company is advancing GX-03, a non-systemic, topical immunomodulator targeting IL-36 and related cytokines, with a primary focus on moderate to severe eczema. The Phase 2 trial for GX-03 is underway, with an interim analysis expected in the first quarter of 2026 and topline data anticipated in the second quarter of 2026. Phase 3 studies are expected to begin in the second half of 2026. Additional pipeline candidates include treatments for onychomycosis and psoriasis, as well as thermostable vaccine platforms. The company’s PermaFusion® technology underpins its proprietary drug delivery approach. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Turn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTurn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 01:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Turn <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Turn Therapeutics Inc. has released a corporate presentation detailing its pipeline and development strategy for inflammatory disease treatments. The company is advancing GX-03, a non-systemic, topical immunomodulator targeting IL-36 and related cytokines, with a primary focus on moderate to severe eczema. The Phase 2 trial for GX-03 is underway, with an interim analysis expected in the first quarter of 2026 and topline data anticipated in the second quarter of 2026. Phase 3 studies are expected to begin in the second half of 2026. Additional pipeline candidates include treatments for onychomycosis and psoriasis, as well as thermostable vaccine platforms. The company’s PermaFusion® technology underpins its proprietary drug delivery approach. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL68h6zc:1","article_id":"2601380069","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601380069","pubTimestamp":1767806396,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Turn Therapeutics Inc. has released a corporate presentation detailing its pipeline and development strategy for inflammatory disease treatments. The company is advancing GX-03, a non-systemic, topical immunomodulator targeting IL-36 and related cytokines, with a primary focus on moderate to severe eczema. The Phase 2 trial for GX-03 is underway, with an interim analysis expected in the first quarter of 2026 and topline data anticipated in the second quarter of 2026. Phase 3 studies are expected to begin in the second half of 2026. Additional pipeline candidates include treatments for onychomycosis and psoriasis, as well as thermostable vaccine platforms. The company’s PermaFusion technology underpins its proprietary drug delivery approach. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TTRX":"Turn Therapeutics (Direct Listing)"},"translate_title":"Turn Therapeutics推出针对湿疹和炎症性疾病的免疫调节平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TTRX":0.9},"content_text":"Turn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases\n    \n\n        Turn Therapeutics Inc. has released a corporate presentation detailing its pipeline and development strategy for inflammatory disease treatments. The company is advancing GX-03, a non-systemic, topical immunomodulator targeting IL-36 and related cytokines, with a primary focus on moderate to severe eczema. The Phase 2 trial for GX-03 is underway, with an interim analysis expected in the first quarter of 2026 and topline data anticipated in the second quarter of 2026. Phase 3 studies are expected to begin in the second half of 2026. Additional pipeline candidates include treatments for onychomycosis and psoriasis, as well as thermostable vaccine platforms. The company’s PermaFusion® technology underpins its proprietary drug delivery approach. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}